↓ Skip to main content
What is this page? Embed badge

Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer Patients

Overview of attention for article published in Therapeutic Drug Monitoring, October 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
63 Mendeley
Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer Patients
Published in
Therapeutic Drug Monitoring, October 2013
DOI 10.1097/ftd.0b013e318290acd2
Pubmed ID
23942539
Authors

Lay Kek Teh, Sharina Hamzah, Hazwanie Hashim, Zakaria Bannur, Zainul Amiruddin Zakaria, Zakaria Hasbullani, John Kwong Siew Shia, Henry Fijeraid, Azmid Md Nor, Mohd Zailani, Prabu Ramasamy, Harris Ngow, Suneet Sood, Mohd Zaki Salleh

Abstract

Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to 5-FU toxicities and death. Association between serum concentration of 5-FU and its related toxicity has also been previously demonstrated. Hence, this study aims to understand the role of DPYD variants in serum level of 5-FU and the risk of developing toxicity to prevent adverse reactions and maximize therapy outcome for personalized medicine.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 63 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 21%
Researcher 10 16%
Student > Ph. D. Student 6 10%
Student > Bachelor 6 10%
Other 5 8%
Other 14 22%
Unknown 9 14%
Readers by discipline Count As %
Medicine and Dentistry 16 25%
Pharmacology, Toxicology and Pharmaceutical Science 13 21%
Agricultural and Biological Sciences 10 16%
Biochemistry, Genetics and Molecular Biology 6 10%
Immunology and Microbiology 3 5%
Other 3 5%
Unknown 12 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2013.
All research outputs
#18,348,542
of 22,723,682 outputs
Outputs from Therapeutic Drug Monitoring
#1,331
of 1,699 outputs
Outputs of similar age
#154,363
of 207,102 outputs
Outputs of similar age from Therapeutic Drug Monitoring
#10
of 12 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,699 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,102 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.